Kazia Therapeutics Limited announced that its chairman, Bryce Carmine, will retire effective March 31, 2026. Carmine, who joined the board as a non‑executive director in June 2015 and was appointed chairman in January 2024, will step down after a decade of leadership that guided the company through a series of strategic milestones.
The retirement follows a significant strategic pivot that saw the company raise $50 million in a private placement in December 2025. The net proceeds of approximately $46.5 million were earmarked to fund the continued clinical development of paxalisib, advance the PD‑L1 degrader program NDL2, and support general corporate purposes. The infusion also addressed Nasdaq listing compliance concerns by boosting the company’s market‑value‑of‑listed‑securities to meet the required threshold, thereby extending the cash runway through the second half of 2028 and into 2029 without incurring debt.
Kazia’s oncology pipeline remains the focus of its growth strategy. Paxalisib, the lead asset, has received FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations and has shown early promise in triple‑negative breast cancer trials. The company also continues preclinical work on NDL2 and EVT801, positioning it to broaden its therapeutic portfolio across high‑need cancer indications.
Governance changes accompany the leadership transition. The board will shrink from four to three directors, with Steven Coffey re‑elected at the March 25, 2026 annual general meeting and Ebru Davidson appointed to the Audit, Risk and Governance Committee. These adjustments aim to streamline decision‑making while maintaining continuity in oversight.
The orderly transition of chairman duties, coupled with a strengthened balance sheet and a clear pipeline roadmap, signals Kazia’s commitment to sustaining its clinical development trajectory and preserving shareholder value in the face of evolving market and regulatory dynamics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.